MTPN

Myotrophin · P58546 · MTPN on Sugi Atlas →

0 patent compounds predicted against MTPN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MTPN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Testosterone and Long Pulse Stimulation After SCI PHASE2COMPLETED
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION) PHASE2COMPLETED
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection PHASE2UNKNOWN
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men nanUNKNOWN
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses nanCOMPLETED
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
Myostatin and Irisin Levels in Predicting the Outcome of Patients With Systemic Inflammation: A Prospective Observational Study nanCOMPLETED
Myotubular and Centronuclear Myopathy Patient Registry nanRECRUITING
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) nanCOMPLETED
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy nanRECRUITING
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 nanRECRUITING
Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy nanCOMPLETED
GDF-15 as a Biomarker for Mitochondrial Disease nanCOMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) nanRECRUITING
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy nanRECRUITING
Observational Cohort Study of Dysferlinopathy in China nanCOMPLETED
Clinical Outcome Study for Dysferlinopathy nanUNKNOWN
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure? nanRECRUITING
Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years nanRECRUITING
Improvement of DIAgnostic and Phenotype-genotype Correlation Studies in Patients With MYOpathy Suspected of TITinopathy nanUNKNOWN
mtDNA Mutation Load Analysis in Mesoangioblasts nanRECRUITING
Mitochondrial Dysfunction in Diabetes nanCOMPLETED
Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease nanCOMPLETED
Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II nanCOMPLETED
Nemaline Myopathy Clinical Research Network (NM-CTRN) nanNOT_YET_RECRUITING
High-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia nanRECRUITING
Nutritional Assessment in Mitochondrial Cytopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MTPN binder may also engage these)

ProteinNameSimilarity
P62775 1.000 P62775 →
Q3T0F7 1.000 Q3T0F7 →
Q863Z4 1.000 Q863Z4 →
P62774 1.000 P62774 →
Q91955 0.998 Q91955 →
Q7T2B9 0.992 Q7T2B9 →
Q7T0Q1 0.988 Q7T0Q1 →
Q6P1S6 0.986 Q6P1S6 →
Q55FM5 0.974 Q55FM5 →
Q9HFE7 0.964 Q9HFE7 →
Q9Z2X3 0.960 Q9Z2X3 →
B0S794 0.960 B0S794 →
Q54HW1 0.957 Q54HW1 →
Q9Z2X2 0.956 Q9Z2X2 →
PSMD10 26S proteasome non-ATPase regulatory subunit 10 0.954 landscape →
Q8VYX1 0.953 Q8VYX1 →
Q4R3S3 0.953 Q4R3S3 →
Q5FWY3 0.952 Q5FWY3 →
Q9BGT9 0.952 Q9BGT9 →
Q10311 0.952 Q10311 →
Q6TGW5 0.952 Q6TGW5 →
Q80YE7 0.952 Q80YE7 →
Q66KY0 0.952 Q66KY0 →
DAPK1 Death-associated protein kinase 1 0.951 landscape →
Q6P686 0.951 Q6P686 →
Q91ZU0 0.951 Q91ZU0 →
P50086 0.951 P50086 →
Q8MJ49 0.950 Q8MJ49 →
A0A1D6NER6 0.950 A0A1D6NER6 →
P0A2U5 0.950 P0A2U5 →